Table 1

MAin characteristics of included studies

Study,
country		N (total)Age
(mean±SD, years)		Male (%)Functional class
(%)		LVEF
(mean±SD, %)		Intervention
(high-dose ACEI)		Control
(low-dose ACEI)		Follow-up (months)
Clement et al25
Belgium		29864.96±10.2469.10I: 12.40
II: 37.95
III: 49.65		NRCaptopril, 50 mg twice dailyCaptopril, 25 mg twice daily24
Nanas et al12
Greece		24856.16±12.6785.10II: 42.05
III: 44.45
IV: 10.75		19.39±8.98Enalapril, 30 mg twice dailyEnalapril, 10 mg twice daily12
The Network Investigators,13
UK		15337063.67II: 64.67
III: 33
IV: 2.33		NREnalapril, 10 mg twice dailyEnalapril, 2.5 mg twice daily or 5 mg twice daily6
Pacher et al26
Austria		8356±9.9983.13II: 2.40
III: 79.52
IV: 18.07		NREnalapril, 20 mg twice dailyEnalapril, 5 mg twice daily12
Packer et al27
USA		316463.60±12.8879.52II: 15.58
III: 77.31
IV: 7.11		23±6Lisinopril, 32.5–35 mg/dayLisinopril: 2.5–5 mg/day36
Riegger,28
Germany		16966*38.6II: 59.3
III: 40.7		NRQuinapril, 10 mg twice daily or 20 mg twice dailyQuinapril, 5 mg twice daily3
van Veldhuisen et al29
The Netherlands, Belgium and Germany		18261.33±8.9679.33II: 77.67
III: 22.33		33.69±8.73Imidapril, 10 mg twice dailyImidapril, 2.5 mg twice daily or 5 mg twice daily3
Widimský et al30
Czech Republic		15257.5±1083II: 25
III: 56
IV: 19		28±8Spirapril, 6 mg once a daySpirapril, 1.5 mg once a day or 3 mg once a day3

  • *Median.

  • ACEI, ACE inhibitor; LVEF, left ventricular ejection fraction; NR, not reported.;